Авдеев Сергей Николаевич

Long-Cov-III-21^{ClinicalTrials.gov}

Efficacy and Safety of Longidaza® for the Treatment of Patients With Residual Changes in the Lungs After COVID-19

^ГРЛС Многоцентровое, рандомизированное, двойное слепое, плацебо-контролируемое исследование в параллельных группах по оценке эффективности и безопасности препарата Лонгидаза®, лиофилизат для приготовления раствора для инъекций, 3000 MЕ (ООО «НПО Петровакс Фарм», Россия), для лечения пациентов с остаточными изменениями в легких после COVID-19

Статус:	Completed
Фаза:	Phase 3
Начало:	8 апреля 2022 г.
Окончание:	31 декабря 2023 г.
Описание:	The goal of this clinical study is to evaluate the efficacy and safety of Longidaza®, lyophilizate for preparation of solution for injection, at a dose of 3000 IU compared to placebo in the treatment of adult patients with residual changes in the lungs after COVID-19 infection
	смотреть на ClinicalTrials.gov

Sur/ARDS-2020^{ClinicalTrials.gov}

Surfactant-BL in Adult Acute Respiratory Distress Syndrome Due to COVID-19

Статус:	Unknown status
Фаза:	не указано
Начало:	3 июля 2020 г.
Окончание:	1 декабря 2021 г.
Описание:	The purpose of this study is to prove the efficacy and safety Surfactant-BL, administered by inhalation in adult hospitalized patients with ARDS due to COVID-19.
	смотреть на ClinicalTrials.gov

NIS-RRU-XXX-2014/1^{ClinicalTrials.gov}

Observational Multicenter Non-interventional Study on COPD Patients Treatment Strategies at the Time of Hospital Discharge and Within 12 Months of Follow-up on an Outpatient Primary Care Basement

Статус:	Completed
Фаза:	не указано
Начало:	31 марта 2015 г.
Окончание:	30 декабря 2016 г.
Описание:	The study is an observational multicenter descriptive study. It is planned to enroll approximately 1250 subjects with severe and very severe COPD hospitalized for the reason of COPD exacerbation into departments of pulmonology or therapy. The study will be conducted in approximately 20-25 institutions of treatment and prevention in Russian Federation and will include about 50 to 60 subject at each clinical site.
	смотреть на ClinicalTrials.gov

Long-Cov-III-21 ClinicalTrials.gov